<DOC>
	<DOCNO>NCT00003641</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . It yet know whether treatment interferon alfa effective observation alone stage II stage III melanoma completely remove surgically . PURPOSE : This randomized phase III trial study high dose interferon alfa see well work compare observation treat patient stage II stage III melanoma completely remove surgery .</brief_summary>
	<brief_title>High-Dose Interferon Alfa Treating Patients With Stage II Stage III Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary Objective : - Compare effect high-dose interferon alfa-2b treatment relapse-free survival patient stage II III resect malignant melanoma . Secondary Objectives : - Compare effect treatment regimen overall survival patient . - Assess toxicity treatment patient . - Compare effect treatment quality life . OUTLINE : This randomize study . Patients stratify pathologic lymph node status ( know vs unknown ) , lymph node staging procedure ( sentinel lymph node procedure vs. elective lymph node dissection vs. lymphadenectomy ) , Breslow depth ( &lt; = 1.0 mm vs. 1.01-2.0 mm vs. 2.01-4.0 mm v &gt; 4.0 mm ) , ulceration primary lesion ( yes vs. vs. unknown ) , disease stage ( lymph node positive [ N1 , N2a ] vs. lymph node negative [ N0 ] ) . Patients randomize one two treatment arm 1:1 ratio . - Arm I ( observation ) : Patients undergo observation 4 week . - Arm II ( Interferon Alfa-2b ) : Patients receive high-dose interferon alfa-2b intravenously ( IV ) 20 minute daily 5 consecutive day . Treatment repeat weekly 4 week absence unacceptable toxicity . Quality life assess treatment , day 22 , every 3 month 2 year , every 6 month 3 year . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter 15 year randomization . PROJECTED ACCRUAL : A total 1,420 patient accrue study 5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically confirm primary melanoma cutaneous origin Stage II ( T3 N0 M0 1.54.0 mm Breslow depth ) Clinically negative regional lymph node pathologic status unknown OR Histologically negative regional lymph node Stage III ( T4 N0 M0 ) Greater 4.0 mm Breslow depth OR Stage III ( T14 N1 ) One lymph node positive microscopically Patients must meet least 1 follow criterion : T2b N0 primary melanoma 1.012.0 mm ulceration , node negative T3ab N0 primary melanoma 2.014.0 mm without ulceration , node negative T4ab N0 primary melanoma &gt; 4.0 mm without ulceration , node negative T1a N1a2a ( microscopic ) primary melanoma thickness microscopically positive lymph node ( number ) Patients positive sentinel node undergo complete lymphadenectomy nodal basin prior study Must complete primary therapy ( wide excision without lymphadenectomy ) randomize study within 84 day wide excision Must undergone adequate wide excision primary lesion Age 18 ( For ECOG patient , patient must &gt; =10 year ) Eastern Cooperative Oncology Group ( ECOG ) Performance status 01 Adequate hematopoietic , hepatic , renal function base follow test : White blood cell ( WBC ) cout least 3,000/mm^3 Platelet count least 125,000/mm^3 Hematocrit least 30 % Bilirubin great 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) , lactate dehydrogenase ( LDH ) , alkaline phosphatase great 2 time ULN If lactate dehydrogenase alkaline phosphatase normal , contrastenhanced compute tomography ( CT ) scan Magnetic resonance imaging ( MRI ) liver require document absence tumor Blood urea nitrogen ( BUN ) great 33 mg/dL OR Creatinine great 1.8 mg/dL No concurrent prior malignancy within past 5 year except : Cancer situ Lobular carcinoma situ breast Carcinoma situ cervix Atypical melanocytic hyperplasia Clark 1 melanoma situ Basal squamous cell skin cancer Negative pregnancy test Fertile patient must use effective contraception 6 month study Clinical , radiological/laboratory , pathological evidence incompletely resect melanoma distant metastatic disease Clinically palpable lymphadenopathy Evidence organic brain syndrome significant impairment basal cognitive function psychiatric disorder would preclude study participation Other significant medical surgical condition , medication treatment regimen , would interfere study participation Pregnant nursing Other history invasive melanoma Autoimmune disorder condition immunosuppression History active ischemic heart disease Cerebrovascular disease Congestive heart failure ( New York Heart Association class III IV heart disease ) Prior concurrent chemotherapy Prior immunotherapy include tumor vaccine , interferon , interleukin , levamisole , biologic response modifier melanoma Concurrent systemic corticosteroid include oral steroid ( i.e. , prednisone , dexamethasone ) , topical steroid cream ointment , steroidcontaining inhaler Prior concurrent radiotherapy Other concurrent immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
</DOC>